>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>AN0128

AN0128

Catalog No.GC63839

AN0128은 붕소 함유 항균 및 항염증제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

AN0128 Chemical Structure

Cas No.: 872044-70-7

Size 가격 재고 수량
5 mg
US$90.00
재고 있음
10 mg
US$153.00
재고 있음
25 mg
US$315.00
재고 있음
50 mg
US$495.00
재고 있음
100 mg
US$855.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

AN0128 is a boron-containing antibacterial and anti-inflammatory agent. AN0128 against S. aureus, S. epidermidis, P. acnes, B. subtilis with minimum inhibitory concentration (MIC) values of 1, 0.5, 0.3, 1 μg/mL. AN0128 can be used for the research of periodontal disease and cutaneous diseases[1][2].

AN0128 (compound 2g; 10 μM; 24-48 hours) shows strong inhibition of the release of pro-inflammatory cytokines (TNF-α, IL-1β) but no inhibition of IFN-γ or IL-4 release in human peripheral blood mononuclear cells (PBMCs)[1].

AN0128 (1%, 5%; daily topical daub for 7 days) significantly reduces the formation of an inflammatory infiltrate and reduces bone loss[2].

[1]. Baker SJ, et al. Identification of a novel boron-containing antibacterial agent (AN0128) with anti-inflammatory activity, for the potential treatment of cutaneous diseases. Bioorg Med Chem Lett. 2006 Dec 1;16(23):5963-7.
[2]. Luan Q, et al. Inhibition of experimental periodontitis by a topical boron-based antimicrobial. J Dent Res. 2008 Feb;87(2):148-52.

리뷰

Review for AN0128

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AN0128

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.